Clinical Research Directory

Inclusion Criteria: * Age : 18-70 years old. * Performance Status : ECOG score 0-2. * Expected to comply with oART (Online Adaptive Radiotherapy) workflow. * Initial Surgical Treatment : Total hysterectomy and bilateral salpingo-oophorectomy ± Pelvic and/or para-aortic lymph node dissection/sampling or sentinel lymph node biopsy. * Pathological Staging \& Histology (per FIGO 2009): Stage I : Grade 3 endometrioid adenocarcinoma with superficial myometrial invasion and extensive LVSI (Lymphovascular Space Invasion). Grade 2 endometrioid adenocarcinoma with deep myometrial invasion and extensive LVSI. Grade 3 endometrioid adenocarcinoma with deep myometrial invasion. Stage II-IIIC1 : Endometrioid carcinoma. Stage I-IIIC1 : Serous carcinoma or clear cell carcinoma. * Informed Consent : * Patients and families fully understand the study protocol. * Voluntarily participate and sign informed consent forms before enrollment Exclusion Criteria: * Prior Radiotherapy : History of abdominal or pelvic irradiation. * Treatment Interval : Without adjuvant chemotherapy: \>12 weeks between surgery and radiotherapy initiation. With adjuvant chemotherapy: \>6 months between surgery and radiotherapy initiation. * Malignancy History : Prior diagnosis of other malignancies. * Pregnancy/Lactation : Pregnant or breastfeeding women. * Active Infection : Fever or uncontrolled active infection. * Inflammatory Bowel Disease (IBD) : History of IBD (regardless of activity status). * Comorbidities : Severe conditions affecting trial compliance, including: Unstable cardiac disease requiring treatment, renal impairment, chronic hepatitis, poorly controlled diabetes, psychiatric disorders